The correlation between adverse events and survival benefits of donafenib in the first-line treatment of advanced hepatocellular carcinoma

被引：0

作者：

Bi, F. ^{[1
]}

Qin, S. ^{[2
]}

Xu, J. ^{[3
]}

Du, C. ^{[4
]}

Fan, Q. ^{[5
]}

Zhang, L. ^{[6
]}

Tao, M. ^{[7
]}

Jiang, D. ^{[8
]}

Wang, S. ^{[9
]}

Chen, Y. ^{[10
]}

Sheng, J. ^{[11
]}

Zhuang, X. ^{[12
]}

Wu, J. ^{[13
]}

Liu, L. ^{[14
]}

机构：

[1] Sichuan Univ, West China Hosp, Dept Med Oncol, Chengdu, Peoples R China

[2] Jinling Hosp, PLA Canc Ctr Nanjing, Nanjing, Peoples R China

[3] Peoples Liberat Army Gen Hosp, Dept Med Oncol, Med Ctr 5, Beijing, Peoples R China

[4] Chongqing Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Chongqing, Peoples R China

[5] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China

[6] Xuzhou Med Univ, Affiliated Hosp, Dept Radiotherapy, Xuzhou, Jiangsu, Peoples R China

[7] Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzhou, Peoples R China

[8] Hebei Med Univ, Hosp 4, Dept Med Oncol, Shijiazhuang, Hebei, Peoples R China

[9] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China

[10] Wenzhou Med Univ, Affiliated Hosp 1, Dept Infect & Liver Dis, Wenzhou, Peoples R China

[11] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Infect Dis, Hangzhou, Peoples R China

[12] Shantou Univ, Coll Med, Canc Hosp, Dept Intervent Therapy, Shantou, Peoples R China

[13] First Peoples Hosp Changzhou, Dept Oncol, Changzhou, Jiangsu, Peoples R China

[14] Suzhou Zelgen Biopharmaceut Co Ltd, Suzhou, Peoples R China

来源：

关键词：

D O I：

10.1016/j.annonc.2021.05.144

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-89

引用

页码：S128 / S128

页数：1